CTI BioPharma (CTIC) Raised to "Buy" at Zacks Investment Research


The firm currently has a $3.00 target price on the biopharmaceutical company's stock. Zacks Investment Research 's price objective indicates a potential upside of 10.70% from the company's previous close.



from Biotech News